Compare KORE & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KORE | VANI |
|---|---|---|
| Founded | 2003 | 1998 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.6M | 95.8M |
| IPO Year | N/A | N/A |
| Metric | KORE | VANI |
|---|---|---|
| Price | $5.07 | $1.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $5.00 | $4.00 |
| AVG Volume (30 Days) | 44.8K | ★ 563.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.26 | N/A |
| Revenue Next Year | $7.55 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.00 | $0.91 |
| 52 Week High | $5.29 | $1.92 |
| Indicator | KORE | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 57.36 | 46.23 |
| Support Level | $4.76 | $1.16 |
| Resistance Level | $5.13 | $1.31 |
| Average True Range (ATR) | 0.22 | 0.09 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 43.64 | 27.27 |
Kore Group Holdings Inc provides Internet of Things (IoT) solutions and services. In addition to providing critical services to customers globally, it enables them to manage, deploy, and scale their IoT applications and use cases. It offers connectivity services, location-based services, device solutions, and managed and professional services for the development and support of IoT technology for the Machine-to-Machine market. It derives revenue from IoT Connectivity services, IoT Solutions services, SIMs (IoT Connectivity), and IoT devices (IoT Solutions). Geographically, the company generates the majority of its revenue from the United States and the rest from other countries.
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.